Racura Oncology
Racura Oncology is a Phase 3 clinical biopharmaceutical company focused on developing cancer therapeutics. Their lead asset, RCDS1 (E,E-bisantrene), targets G4-DNA & RNA binding to inhibit MYC, a key cancer growth regulator, and is being advanced in multiple oncology indications.
Short position
Racura Oncology (ASX:RAC) has 0.01% of its shares on issue reported as short positions as of 5 Oct 2026, or about 19,354 shares. Over the past 30 days that figure has been broadly flat, and over 90 days it has been broadly flat. RAC is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4Racura Oncology (RAC) financials
Results, ratios and statements
Latest result
Year to 30 Jun 2026 (FY26) vs FY25, figures in AUD, the reporting currency
- Revenue
- $3.4MM (source: ASX (Markit))vs $788.4KM (source: ASX (Markit)) (FY25)
- ASX (Markit), as at 29 Sep 2026
- NPAT
- −$11.1Mvs −$4.8M (FY25)
- Yahoo Finance, as at 29 Sep 2026
- EPS (diluted)
- −$0.062vs −$0.028 (FY25)
- Yahoo Finance, as at 29 Sep 2026
- Rev YoY
- +334.3%FY
- EPS YoY
- n/aFY
- ASX (Markit)
Key ratios
Year to 30 Jun 2026 (FY); balance sheet at 30 Jun 2026; prices to 9 Oct 2026
- Gross margin
- n/a
- Operating margin
- −390.6%
- Net margin
- −323.8%
- FCF margin
- −240.9%
- ROE
- −42.3%
- ROA
- −39.9%
- FCF conversion
- n/a
- Net debt (excl. leases)
- n/a
- Net debt / EBITDA
- n/a
- Current ratio
- 21.4×
- Interest cover
- n/a
- Cash dividends paid / net profit
- n/a
- Market cap
- $355.9M
- P/E
- n/a
- P/B
- 9.8×
Ratios use the reporting currency (AUD); market cap is in AUD. Sources: Yahoo Finance and ASX (Markit), as at 29 Sep 2026.
Financial statements
Figures in AUD, the reporting currency; Yahoo Finance unless marked
| Line item | FY26 | FY25 | FY24 | FY23 |
|---|---|---|---|---|
| Revenue | $3.4MM (source: ASX (Markit)) | $788.4KM (source: ASX (Markit)) | $832.6KM (source: ASX (Markit)) | $591.8KM (source: ASX (Markit)) |
| Operating income | −$13.4M | −$10.8M | −$18.7M | −$13.6M |
| EBITDA | −$13.1M | −$10.5M | −$18.4M | −$13.4M |
| EBIT | −$13.4M | −$10.8M | −$18.7M | −$13.6M |
| Pretax income | −$11.1M | −$4.8M | −$13.8M | −$9.9M |
| Tax | $0 | $0 | $0 | $0 |
| NPAT | −$11.1M | −$4.8M | −$13.8M | −$9.9M |
| Net interest income | $613.3K | $788.4K | $832.6K | $591.8K |
| EPS basic | −$0.062 | −$0.028 | −$0.084 | −$0.062 |
| EPS diluted | −$0.062 | −$0.028 | −$0.084 | −$0.062 |
| Shares | 196.1M | 173.7M | 170.3M | 163.1M |
- ASX (Markit)
Financial reports
The company's own filings, newest first
- Appendix 4E & Annual ReportAnnual Results25 Aug 2026via asx_announcements
- June 2026 Quarterly Activities Report and Appendix 4CQuarterly Report28 Jul 2026via asx_announcements
- March 2026 Quarterly Activity Report and Appendix 4CQuarterly Report30 Apr 2026via asx_announcements
- Appendix 4D & Half-Year Financial StatementsHalf Year Results27 Feb 2026via asx_announcements
- December 2025 Quarterly Activity Report and Appendix 4CQuarterly Report29 Jan 2026via asx_announcements
- September 2025 Quarterly Activity Report and Appendix 4CQuarterly Report31 Oct 2025via asx_announcements
- Appendix 4E & Annual ReportAnnual Results26 Aug 2025via asx_announcements
- June 2025 Quarterly Activity Report and Appendix 4CQuarterly Report23 Jul 2025via asx_announcements
- March 2025 Quarterly Activity Report and Appendix 4CQuarterly Report23 Apr 2025via asx_announcements
- Appendix 4D & Half-Year Financial StatementsHalf Year Results25 Feb 2025via asx_announcements
Showing 10 of 20 reports